Peer Review Integrity in Biotechnology

Introduction

Peer review integrity in biotechnology means ensuring that scientific research is assessed fairly, independently, confidentially, and on the basis of reliable evidence. Biotechnology research includes genetic engineering, gene editing, stem-cell research, synthetic biology, vaccines, and genetically modified organisms. Because such research can affect human health, biodiversity, public safety, and commercial interests, dishonest or biased peer review may cause serious scientific and legal consequences. The Committee on Publication Ethics (COPE) provides internationally recognised guidance on reviewer impartiality, confidentiality, and disclosure of conflicts of interest.

COPE: Committee on Publication Ethics

+1

Legal and Ethical Framework

Peer review integrity involves several important principles:

Impartiality: Reviewers must assess scientific methods, evidence, reproducibility, and conclusions without discrimination or personal rivalry.

Confidentiality: Unpublished biotechnology research, genetic data, experimental methods, and intellectual property must not be disclosed or used for personal advantage.

Conflict of interest: Reviewers should disclose financial relationships with biotechnology companies, competing patents, research collaborations, or personal relationships with authors.

Scientific accuracy: Reviewers should identify fabricated data, plagiarism, inadequate ethical approval, misleading claims, and weaknesses in experimental design.

Responsible use of artificial intelligence: Confidential manuscripts should not be uploaded to AI systems unless the journal’s rules and applicable confidentiality and data-protection requirements permit it.

publicationethics.org

+2

In India, relevant legal protections may arise under the Indian Contract Act, 1872, the Copyright Act, 1957, the Patents Act, 1970, and applicable data-protection law, depending on the circumstances. These laws do not create one comprehensive statutory code specifically governing biotechnology peer review. Journal policies, institutional research-integrity rules, research ethics requirements, and contractual obligations also play important roles.

Important Case Laws

1. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013): The US Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated, while synthetically created cDNA may be patent-eligible subject to the judgment’s qualifications. Although this was not a peer-review case, it illustrates why biotechnology reviewers must carefully assess the scientific and legal basis of claims involving genetic material.

2. Diamond v. Chakrabarty, 447 U.S. 303 (1980): The US Supreme Court recognised the patent eligibility of a genetically engineered microorganism. The case demonstrates the importance of rigorous evaluation of biotechnology inventions and their claimed technical contributions. It is relevant by analogy, not a direct ruling on peer-review misconduct.

3. Harcombe v Associated Newspapers Ltd [2024] EWHC 1523 (KB): This English High Court decision concerned defamation and statements associated with peer-reviewed scientific material. It illustrates that disputes surrounding scientific publications can raise legal questions about the reliability and treatment of peer-reviewed work. It did not establish a comprehensive legal code for peer-review integrity.

Conclusion

Peer review integrity is essential to trustworthy biotechnology research. Reviewers, editors, researchers, and institutions should maintain confidentiality, disclose conflicts, verify scientific evidence, and investigate credible allegations of misconduct. The cited cases provide useful context on biotechnology patentability and disputes involving scientific publications, but they are not direct judicial precedents establishing a standalone offence of improper biotechnology peer review.

COPE: Committee on Publication Ethics

+1